Embecta (NASDAQ:EMBC) Director Milton Mayo Morris Sells 6,293 Shares

Embecta Corp. (NASDAQ:EMBC) Director Milton Mayo Morris sold 6,293 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $5.88, for a total value of $37,002.84. Following the transaction, the director directly owned 53,828 shares in the company, valued at approximately $316,508.64. The trade was a 10.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Embecta Stock Down 4.3%

Shares of EMBC stock opened at $5.55 on Wednesday. Embecta Corp. has a 52 week low of $2.77 and a 52 week high of $15.55. The company has a 50 day moving average price of $4.22 and a 200-day moving average price of $5.77. The firm has a market capitalization of $314.46 million, a PE ratio of 3.75 and a beta of 0.86.

Embecta (NASDAQ:EMBC) last announced its earnings results on Friday, August 7th. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.29. The business had revenue of $271.70 million during the quarter, compared to analyst estimates of $254.53 million. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The company’s quarterly revenue was down 8.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.12 EPS. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. Analysts anticipate that Embecta Corp. will post 1.84 earnings per share for the current year.

Embecta Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Thursday, August 27th will be given a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a yield of 0.7%. The ex-dividend date is Thursday, August 27th. Embecta’s payout ratio is 2.70%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on EMBC shares. Weiss Ratings lowered Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, August 3rd. Bank of America lowered their target price on Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a research report on Monday, May 18th. Finally, Zacks Research raised Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. Three investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $11.00.

Institutional Investors Weigh In On Embecta

Several institutional investors and hedge funds have recently modified their holdings of EMBC. Royal Bank of Canada boosted its position in shares of Embecta by 38.3% during the first quarter. Royal Bank of Canada now owns 18,201 shares of the company’s stock worth $232,000 after acquiring an additional 5,036 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Embecta by 3.7% during the 1st quarter. AQR Capital Management LLC now owns 225,641 shares of the company’s stock valued at $2,738,000 after purchasing an additional 8,109 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Embecta by 2.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock worth $629,000 after purchasing an additional 1,159 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Embecta by 4.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 172,173 shares of the company’s stock valued at $2,195,000 after buying an additional 7,894 shares in the last quarter. Finally, Jane Street Group LLC increased its stake in Embecta by 224.0% in the 1st quarter. Jane Street Group LLC now owns 132,688 shares of the company’s stock worth $1,692,000 after acquiring an additional 91,729 shares during the last quarter. Institutional investors own 93.83% of the company’s stock.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.